Experts call for a new booster dose of the bivalent vaccine to be provided urgently
In this new wave of covid-19, most of the hospitalized are elderly, immunosuppressed (transplanted, oncological, etc.) São Paulo heard from Estadão The low adherence to booster vaccinations and the circulation of new Ômicron subvariants are among the main reasons of the return of the disease.
“What we know about this subvariant is that it transmits more, it infects more,” says Professor Ludhmila Hajjar, an intensivist at Vila Nova Star Hospital, a private unit in south São Paulo. “The people currently hospitalized are mostly elderly,” she says.
“Among the hospitalized there are people with an incomplete vaccination program – with only two doses mainly – or who have not been vaccinated,” reports Carla Kobayashi, an infectious disease specialist at Sírio-Libanês. The profile of hospitalized patients, adds the doctor, also includes the elderly with comorbidities or serious pathologies.
About 69 million Brazilians may have already taken the 3rd dose of the immunizer and have not gone to health centers. The balance was released by the minister of the area, Marcelo Queiroga, on weekends.
Infectologist Raquel Stucchi, from Campinas State University (Unicamp), has a similar report to that of her colleagues. “The elderly and the immunocompromised have already had a long time since they completed the vaccination with four and five doses respectively. Therefore, it would be urgent that we already have a plan for another additional dose, which should preferably be done with the bivalent vaccine” . , stick up for.
The second generation vaccine is a bet abroad
To halt the advance of new variants of Ômicron, other countries, such as the United States and some Europeans, have started applying a more current version of the covid-19 vaccine. Called bivalent, the protection is manufactured by Pfizer and is effective against multiple strains simultaneously: according to the company, they protect against Ômicron’s BA.1, BA.4 and BA.5 versions.
The arrival of the most protective immunizer in the country is not yet expected. Pfizer asked the National Health Surveillance Agency (Anvisa) in October for the urgent use of the vaccine. Last week the federal agency announced that it was in the final phase of analysis by the technical area, but there is still no date for the final deliberation.to the.
🇧🇷The best content in your email for free. Choose your favorite Terra newsletter. Click here!
Source: Terra
Ben Stock is a lifestyle journalist and author at Gossipify. He writes about topics such as health, wellness, travel, food and home decor. He provides practical advice and inspiration to improve well-being, keeps readers up to date with latest lifestyle news and trends, known for his engaging writing style, in-depth analysis and unique perspectives.
